arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Anika Therapeutics, Inc.

ANIK
$21.48 ▲ +1.32 (+6.55%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
67 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
27
Health
Poor
Bearish
auto_awesome

Analytical Summary

Anika Therapeutics, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $286.3M
Dividend Yield
Revenue Growth 15.6%
Op. Margin 9.1%
ROIC 2.1%
FCF / Share $-0.16
Trailing P/E 85.9x
Price / Book 2.1x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$32.61M
↑ +15.6%
Net Income Profit after all expenses
$-5.06M
↓ -3.8%
Operating Margin Operating profit as % of sales
9.1%
↑ +148.9% 15th
FCF / Share Free cash flow per share
$-0.16
↑ +65.5%
Long-Term Debt Long-term obligations
$25.00M
↓ -50.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
24
Returns
36
Cash Quality
14

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters